Omnicell, Inc. (NASDAQ:OMCL – Get Rating) EVP Scott Peter Seidelmann sold 3,765 shares of the business’s stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $110.15, for a total value of $414,714.75. Following the completion of the transaction, the executive vice president now directly owns 40,789 shares in the company, valued at approximately $4,492,908.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of OMCL traded down $2.88 during trading hours on Friday, hitting $107.07. 808,605 shares of the stock traded hands, compared to its average volume of 432,854. Omnicell, Inc. has a 1-year low of $104.32 and a 1-year high of $187.29. The firm has a market capitalization of $4.73 billion, a PE ratio of 71.86, a price-to-earnings-growth ratio of 2.07 and a beta of 1.21. The business has a fifty day moving average of $113.41 and a 200-day moving average of $138.45.
Omnicell (NASDAQ:OMCL – Get Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.13. Omnicell had a return on equity of 11.35% and a net margin of 6.00%. The business had revenue of $319.00 million for the quarter, compared to analyst estimates of $313.98 million. During the same quarter in the prior year, the firm posted $0.62 earnings per share. The firm’s revenue for the quarter was up 26.7% compared to the same quarter last year. As a group, equities research analysts expect that Omnicell, Inc. will post 2.73 earnings per share for the current year.
A number of equities analysts have commented on OMCL shares. TheStreet lowered Omnicell from a “b-” rating to a “c+” rating in a research note on Tuesday, May 17th. Wells Fargo & Company reduced their price objective on Omnicell from $188.00 to $158.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 3rd. StockNews.com started coverage on Omnicell in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Piper Sandler cut their price target on Omnicell from $181.00 to $162.00 in a research note on Monday, May 2nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell currently has an average rating of “Buy” and an average price target of $186.25.
About Omnicell (Get Rating)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
- Get a free copy of the StockNews.com research report on Omnicell (OMCL)
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.